Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Feb 16;19(1):14.
doi: 10.1186/s12969-021-00502-8.

Prevalence and significance of serum 14-3-3η in juvenile idiopathic arthritis

Affiliations

Prevalence and significance of serum 14-3-3η in juvenile idiopathic arthritis

Iris Reyhan et al. Pediatr Rheumatol Online J. .

Abstract

Background: Prompt diagnosis of juvenile idiopathic arthritis (JIA) is important to avoid long term complications. Elevated serum 14-3-3η levels improve the diagnostic sensitivity of rheumatoid factor (RF) and cyclic citrullinated peptide (CCP) antibody in adult rheumatoid arthritis (RA), and have been associated with more severe phenotype. We investigated the prevalence and clinical significance of serum 14-3-3η in different types of JIA.

Methods: JIA patients (n = 151) followed by the Pediatric Rheumatology Core at Children's Hospital of Los Angeles were categorized into 5 groups: polyarticular JIA RF+ (PJIA RF+; n = 39), PJIA RF- (n = 39), psoriatic arthritis (PsA; n = 19), enthesitis-related arthritis (ERA; n = 18), and oligoarticular JIA (OJIA [control group]; n = 36). RF, CCP antibody, and 14-3-3η were measured for all patients. 14-3-3η serum levels > 0.2 ng/mL were considered positive. Disease activity was assessed by the Juvenile Arthritis Disease Activity Score-71 (JADAS-71).

Results: Elevated 14-3-3η levels were detected in 34/151 (23%) patients, and across all groups tested. Most patients with 14-3-3η had titers ≥4 times above the cutoff value. The majority (22, 65%) of 14-3-3η-positive patients were also positive for RF or CCP antibodies, 16 (47%) were positive for all 3, and 12 (35%) were single-positive for 14-3-3η. The highest prevalence of 14-3-3η was in PJIA RF+ patients (49%), followed by OJIA (22%). Positivity for 14-3-3η was not significantly associated with disease activity or age at diagnosis.

Conclusion: Serum 14-3-3η can be detected in all forms of JIA tested but appears to be most common in PJIA RF+. 14-3-3η does not appear to correlate with disease activity in JIA.

Keywords: 14–3-3η(eta); Biomarker; CCP antibody; Juvenile idiopathic arthritis; Rheumatoid factor.

PubMed Disclaimer

Conflict of interest statement

Multiple researchers involved in our study are or were Quest Diagnostics employees and one employee had stock at Quest Diagnostics in the last year.

Iris Reyhan MD.

Conflict of Interest: None.

Olga S. Zhukov, MS MB (ASCP).

Conflict of Interest: Quest Diagnostics Employee, stock, stock options.

Robert J. Lagier, MS.

Conflict of Interest: Quest Diagnostics Employee.

Robert F. Bridgforth.

Conflict of Interest: former Quest Diagnostics Employee.

Gary J. Williams, PhD.

Conflict of Interest: former Quest Diagnostics Employee, stocks.

Joanna M. Popov, MD PhD.

Conflict of Interest: Quest Diagnostics Employee.

Stanley J. Naides, MD.

Conflict of Interest: formerly Quest Diagnostics Employee, stock, stock options.

Andreas Reiff, MD.

Conflict of Interest: None.

Figures

Fig. 1
Fig. 1
14-3-3η level within different JIA groups

Similar articles

Cited by

References

    1. Beukelman T, Patkar NM, Saag KG, Tolleson-Rinehart S, Cron RQ, DeWitt EM, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res (Hoboken) 2011;63(4):465–482. doi: 10.1002/acr.20460. - DOI - PMC - PubMed
    1. Gillima BE, Chauhan AK, Moore TL. Evaluation of anti-citrullinated type II collagen and anti-citrullinated vimentin antibodies in patients with juvenile idiopathic arthritis. Pediatr Rheumatol. 2013;11:13. doi: 10.1186/1546-0096-11-31. - DOI - PMC - PubMed
    1. Hamooda M, Fouad H, Nermeen G, Sewelam N, Magahed D. Anti-cyclic citrullinated peptide antibodies in children with juvenile idiopathic arthritis. Electron Physician. 2016;8(9):2891–2903. doi: 10.19082/2897. - DOI - PMC - PubMed
    1. Kuna AT, Lamot L, Miler M, Harjacek M, Simundic AM, Vrkic N. Antibodies to mutated citrullinated vimentin and antibodies to cyclic citrullinated peptides in juvenile idiopathic arthritis. Clin Chem Lab Med. 2009;47(12):1525–1530. doi: 10.1515/CCLM.2009.288. - DOI - PubMed
    1. Oberle EJ, Harris JG, Verbsky JW. Polyarticular juvenile idiopathic arthritis – epidemiology and management approaches. Clin Epidemiol. 2014;6:379–393. doi: 10.2147/CLEP.S53168. - DOI - PMC - PubMed